Browsing Tag
generalized myasthenia gravis
3 posts
Is the gMG treatment race entering a lower-burden dosing phase?
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis treatment, REGN stock sentiment and siRNA competition today!
Can UPLIZNA transform gMG treatment? Amgen’s FDA win sets new benchmark for antibody-positive patients
Discover how Amgen’s UPLIZNA is redefining generalized myasthenia gravis treatment after FDA approval. Find out what this means for patients and investors.
Johnson & Johnson posts sustained superiority for IMAAVY in gMG vs rival FcRn blockers in 24-week indirect comparison
New 24-week comparison shows Johnson & Johnson’s IMAAVY outperforms other FcRn blockers in gMG control—see what this means for patients and investors.